Neuropsychiatry

Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
Giovedì, Maggio 9, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, Annual general meeting, Therapy, Port, Somnolence, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • Our proprietary Glyph™ platform allows SPT-300 to be absorbed like a dietary fat through the intestinal lymphatic system and transported into circulation.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
Giovedì, Maggio 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, Human, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, PRTC, Annual general meeting, Therapy, Somnolence, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • The most common treatment-emergent adverse event was somnolence (29% SPT-300 vs. 13% placebo), which was transient and mild or moderate.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

Retrieved on: 
Martedì, Maggio 7, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Risk, Daphne, Innovation, Neuropsychiatry, Culture, Biomarker, Genzyme, Synageva, Sleep, Karuna, Yale University, Harvard Medical School, PRTC, Bristol Myers Squibb, Therapy, Alnylam Pharmaceuticals, Management, DSM-IV codes, Johnson & Johnson, Eli Lilly, Neuroscience, Depression, University of Michigan, Chemical engineering, Multimedia, Anxiety, Organization, Stanford University, University, PureTech Health, RNA interference, Lymphatic system, P&L, Patient, Acquisition, Pleasure, MBA, Growth

View the full release here: https://www.businesswire.com/news/home/20240507753971/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507753971/en/
    PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments (Graphic: Business Wire)
    The appointments follow the recent launch of Seaport , PureTech’s newest Founded Entity, with a $100 million Series A financing round.
  • Following the Series A financing, PureTech holds equity ownership in Seaport of 61.5 percent on a diluted basis.
  • In addition, Michael Chen, Ph.D., Co-founder, was named Chief Scientific Officer, and Eric Green, MBA, was appointed Chief Operating Officer.
  • The appointments follow the recent launch of Seaport with a $100 million Series A financing round to advance the development of novel neuropsychiatric medicines.

Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments

Retrieved on: 
Martedì, Maggio 7, 2024
Health, Pharmaceutical, Risk, Daphne, Innovation, Neuropsychiatry, Culture, Biomarker, Genzyme, Synageva, Sleep, Karuna, Yale University, Harvard Medical School, Bristol Myers Squibb, Therapy, Alnylam Pharmaceuticals, Management, DSM-IV codes, Johnson & Johnson, Eli Lilly, Neuroscience, Depression, University of Michigan, Chemical engineering, Anxiety, Organization, Stanford University, University, PureTech Health, RNA interference, Lymphatic system, P&L, Science, Patient, Acquisition, Pleasure, MBA, Growth

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the appointment of Denice Torres, J.D., to its Board of Directors.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the appointment of Denice Torres, J.D., to its Board of Directors.
  • The appointments follow the recent launch of Seaport with a $100 million Series A financing round to advance the development of novel neuropsychiatric medicines.
  • “We are incredibly honored to welcome Denice to our Board of Directors.
  • She is an exceptional healthcare leader with a track record of successfully guiding organizations through significant growth and transformation,” said Steve Paul, M.D., Founder and Chair of the Board of Directors at Seaport.

Leading Global Biotechnology Company Selects ValGenesis iRisk to Advance Its Pipeline of Critical Drug Therapies

Retrieved on: 
Martedì, Aprile 16, 2024
Software, Biotechnology, Pharmaceutical, Health, Data Management, Infectious Diseases, Health Technology, Technology, Knowledge management, Risk management, Neuropsychiatry, Neurology, Workflow

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a leading global biotechnology company selected ValGenesis iRisk to digitalize the quality risk management processes across its manufacturing sites.

Key Points: 
  • ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a leading global biotechnology company selected ValGenesis iRisk to digitalize the quality risk management processes across its manufacturing sites.
  • A pioneer in scientific research for complex and devastating diseases, the company is advancing a pipeline of potential critical drug therapies across neurology, neuropsychiatry, specialized immunology, and rare diseases.
  • Hearing about iRisk from a ValGenesis customer, the company approached ValGenesis to implement iRisk at its headquarters in the United States, to support its small molecule drug product development team in the digitalization of its quality risk management processes.
  • “Having the best risk management tools gathered collectively under ValGenesis iRisk is a game changer for customers.

Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group

Retrieved on: 
Mercoledì, Marzo 27, 2024
Depression, Neuropsychiatry, Partner, Psychiatry, ADHD, Mental, Partnership, LMHC, Transcranial magnetic stimulation, TMS, News, Acquisition, Brain, Region, Physician, Health, Dementia, Practitioner, Nursing

"We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.

Key Points: 
  • "We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.
  • Established in 2016, The Neuropsychiatry & TMS Group, led by Dr. Ahmed, has been dedicated to delivering exceptional mental health services.
  • With the support of Beacon, The Neuropsychiatry & TMS Group anticipates continued growth opportunities, including expanding its TMS services and recruiting additional physicians.
  • “I am pleased to announce our recent expansion into Florida, a natural progression for Beacon,” says Beacon Behavioral Partners CEO Sean Wendell.

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

Retrieved on: 
Martedì, Marzo 26, 2024
MGH, Harvard Medical School, Public health, Mass General Brigham, Massachusetts General Hospital, MDD, Patient, Public, Roche, Research, Merck, Social anxiety disorder, DSM-IV codes, Bristol Myers Squibb, Clinical trial, Neuropsychiatry, HMS, World Health Organization, Therapy, Hospital, Safety, WHO, SAD, Major depressive disorder, PTSD, Mass, Pharmaceutical industry

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Key Points: 
  • Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
  • “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, Head of Clinical Trials at Healis Therapeutics.
  • General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, Co-Founder of Healis Therapeutics.

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Martedì, Aprile 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Martedì, Aprile 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Lunedì, Marzo 25, 2024
Biotechnology, Cardiology, Health, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • “The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, “We’re proud to be part of Gedeon Richter’s plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services.”